Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma

被引:107
作者
Chansky, K
Benedetti, J
Macdonald, JS
机构
[1] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[2] St Vincents Comprehens Canc Ctr, Div Med Oncol, New York, NY USA
关键词
5-fluorouracil; colorectal carcinoma; toxicity; gender; classification trees; clinical trials;
D O I
10.1002/cncr.20878
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Recent explorations suggest that women may experience more severe 5-fluorouracil (5-FU)-related toxicity than men. The patient Populations from 4 Southwest Oncology Group colorectal carcinoma trials with 5-FU-containing regimens were examined for toxicity differences between the genders. METHODS. The current Study included 1074 patients froin 4 trials. Hypotheses regarding differences in specific toxicities were generated via exploratory analyses on the data from the 2 earlier trials (n = 505 patients), using basic univariate techniques and classification tree methods. Validation of these hypotheses was performed on data from the 2 later trials (n = 569 patients) using logistic regression models for dichotomous toxicity outcomes and rank-SLIM tests for comparisons of overall toxicity grade. RESULTS. 5-FU toxicity was more extensive in women than in men in terms of average maximum toxicity grade (P = 0.005), number of different types of toxicity experienced (P = 0.009), and incidence of severe toxicities (P = 0.02). The incidence of greater than or equal to Grade 2 hematologic toxicity in the 2 later trials was higher in women than in men and women experienced more frequent moderate to severe mucositis compared with men. CONCLUSIONS. Differences in 5-FU toxicity profiles between men and women were hypothesized after an exploratory analysis, and then verified by an independent confirmatory analysis using data from the 2 later trials. This process provided Substantial evidence for gender differences in specific aspects of 5-FU toxicity that persist across a range of treatment regimens, patient characteristics, and cancer trial settings.
引用
收藏
页码:1165 / 1171
页数:7
相关论文
共 20 条
[1]  
[Anonymous], 1997, CLIN TRIALS ONCOLOGY
[2]  
Breiman L., 1998, CLASSIFICATION REGRE
[3]  
CIAMPI A, 1987, BIOSTATISTICS
[4]  
DEVITA VT, 1993, CANC PRINCIPALS PRAC
[5]  
Fleming T., 1995, DRUG INF J, V29, p1681S
[6]  
FRANCHI F, 1991, MED ONCOL TUMOR PHAR, V8, P69
[7]   SOUTHWEST-ONCOLOGY-GROUP STANDARD RESPONSE CRITERIA, END-POINT DEFINITIONS AND TOXICITY CRITERIA [J].
GREEN, S ;
WEISS, GR .
INVESTIGATIONAL NEW DRUGS, 1992, 10 (04) :239-253
[8]  
HARRIS BE, 1991, CANCER, V68, P499, DOI 10.1002/1097-0142(19910801)68:3<499::AID-CNCR2820680309>3.0.CO
[9]  
2-F
[10]   Cancer statistics, 2002 [J].
Jemal, A ;
Thomas, A ;
Murray, T ;
Thun, M .
CA-A CANCER JOURNAL FOR CLINICIANS, 2002, 52 (01) :23-47